Evidence map›Paper›PMID 42869508›Full record

ArticleBMJ open respiratory research2026

Protocol and rationale for a randomised, double-blind, placebo-controlled phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF.

Toby M Maher, Fernando Martinez, Michael Kreuter, Tamera J Corte, Marlies Wijsenbeek, Takashi Ogura, Takafumi Suda, Zuojun Xu, Aryeh Fischer, Yue Wang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Toby M MaherKeck School of Medicine of USC, University of Southern California, Los Angeles, California, USA tobymahe@usc.edu.ORCID http://orcid.org/0000-0001-7192-9149
Fernando MartinezUniversity of Massachusetts Chan Medical School/UMass Memorial Health System, Worcester, Massachusetts, USA.ORCID http://orcid.org/0000-0002-2412-3182
Michael KreuterLung Center Mainz, University Medical Center, Mainz and Marienhaus Clinic Mainz, Mainz, Germany.
Tamera J CorteRoyal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Marlies WijsenbeekCenter of Expertise for Interstitial Lung Disease and Sarcoidosis, Erasmus MC, University Hospital, Rotterdam, The Netherlands.
Takashi OguraKanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
Takafumi SudaHamamatsu University School of Medicine, Hamamatsu, Japan.
Zuojun XuPeking Union Medical College Hospital, Beijing, China.
Aryeh FischerBristol Myers Squibb, Princeton, New Jersey, USA.
Yue WangBristol Myers Squibb, Princeton, New Jersey, USA.
Elizabeth CerulloBristol Myers Squibb, Princeton, New Jersey, USA.
Walid ElsharkawiBristol Myers Squibb, Princeton, New Jersey, USA.
Aditya PatelBristol Myers Squibb, Princeton, New Jersey, USA.
Vincent CottinNational French Reference Coordinating Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, ERN-LUNG, UMR 754, INRAE, University Claude Bernard, Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Idiopathic Pulmonary FibrosisRespiratory Function Test

Identifiers

PMID42869508
PMCPMC13656158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.